

# NEWS 02 2016

Celebrating 40 Years of Biological activities.

**Lugano, March 11<sup>th</sup> 2016** – On this day, 40 years ago, Bioferment S.A. was officially registered in Lugano as a company dedicated to the manufacturing of products derived from fermentation and various other pharmaceutical fields, and started operations.



The very first product under development by Bioferment was, a pharmaceutical Probiotic, ***Enterococcus faecium SF68***® (see [link](#) for more details), launched as a pharmaceutical prescription drug in Switzerland, Italy and Austria under the name of Bioflorin® in the 80's.

The second product line developed by Bioferment on animal health was launched in the 90's by several partners, including Roche Vitamins (now DSM), and has seen rapid growth in recent years. In fact, the application of probiotics in animal nutrition represents, nowadays, a modern and natural way to improve zootechnical performances as well as the health and welfare of farm animals being that the use of Antibiotics as growth promoters is becoming more widely prohibited

*"I'm proud to represent the third generation of the proprietorship of a successful and innovative company that was founded by our grandfathers"* confirms Anton Van Troostenburg, Cerbios' President.

*"Leading it through the turmoils of the current times, while maintaining the original entrepreneurial spirit and corporate culture, is an exciting challenge. I'm confident that we'll reap many more years of successes and growth."*



The success and expertise of Bioferment with its strain *Enterococcus faecium SF68*® was also the reason why Cerbios became active as a contract manufacturer on an exclusive basis for **Pharmaceutical Probiotics** in 2003.

The evolution of the Biological Division was initiated in the late 90's with the novel enterprise of entering into the world of **Recombinant Proteins** based on CHO mammalian cells.



The expertise acquired on the internal development of **Recombinant Urokinase** ([patented](#)) and the investments made in the past years in both [cGMP facilities](#) and [new R&D laboratories](#), has opened up new opportunities as an [exclusive contract manufacturer](#) for originators in the area of **monoclonal antibodies** and recombinant proteins.

*"The evolution of the original Bioferment activities over the last years is very promising for the future of the Cerbios' Biological Division" confirms Gabriel Haering, CEO. "In addition to the products and services offered in both areas, Probiotics and Recombinants, the synergy of both divisions, Chemical and Biological, is taking place with the [development and manufacturing of Antibody-Drug-Conjugates \(ADCs\)](#) on an exclusive basis".*



As a final curious note: the original Bioferment name is still partially present in Cerbios' company name that was created in 1994 as a merger of the three companies owned by the same shareholders in Lugano: **CER**nitin SA, **BIO**ferment SA, **Sa**pec SA = CERBIOS.

For further information, please contact:

**Cerbios-Pharma SA**

Via Figino 6  
6917 Barbengo/Lugano  
SWITZERLAND

Phone +41 (0) 91 985 63 11  
Fax +41 (0) 91 985 63 25  
email [info@cerbios.ch](mailto:info@cerbios.ch)

About Cerbios-Pharma SA

Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide.

Exclusive, third-party manufacturing services are offered by the Chemical Division for HPAs and by the Biological Division for monoclonal antibodies, recombinant proteins and pharma probiotics.

Cerbios provides full CMC support to its world-wide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios' commercial products are marketed worldwide but primarily in Europe, USA, Japan and India